Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by $2.20, provides guidance
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $246.81 --0%
Revenue Growth %: +7.1%
Financial Fact:
Intangible asset amortization: 26.45M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +7.1%
Financial Fact:
Intangible asset amortization: 26.45M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $8.13, $2.20 better than the analyst estimate of $5.93. Revenue for the quarter came in at $1.13 billion versus the consensus estimate of $1.11 billion.
GUIDANCE:
Jazz Pharmaceuticals sees Q4 2025 revenue of $4.175-4.275 billion, versus the consensus of $4.221 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- StoneX Reiterates Buy Rating on Hut 8 Mining Corp. (HUT)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
